PSMA PET/CT has shown high detection rates (98–100%) for the primary prostate tumor [46,47,48], and provides more sensitive screening for metastatic disease at initial staging than conventional imaging modalities [8]. Here, FOLH1 is linked to metastatic neoplasm.